At MVC we have chosen a tried and tested technology platform as novel vaccine technologies face novel challenges
In Conversation
Norway has the opportunity to use its registries, pilot pay for performance schemes, and initiate innovative contracting, so that payment is only made when something works,…
In a world seemingly turning ever faster and becoming more divided and polarized, it’s an asset to have institutions that stick to their mission
For advanced therapies, market approval is not the end of the journey, and we really want to reach the final destination, which is having patients benefit…
A successful culture needs to guard against complacency. We must stay hungry
One of the most common questions we received from clients is, who responded the best during the first wave of the pandemic? The answer is simple:…
We have now sold the Epishuttle to customers in more than 20 countries. It is playing a crucial role in tackling the COVID-19 pandemic
Norway is a very good country to start projects. In the pre-seed and seed stage people here are very investment-minded and there are a lot of…
I personally feel very privileged to work in an organization with such a rich heritage and major impact on people’s lives
Despite the COVID-19 pandemic, this year’s results have been even better than last year’s; a testament to Switzerland’s resilience and its strong appeal as a safe…
We will only see the massive advantages of individualised medicine in Norway when we really change the system
Attractive conditions must be maintained both for the large pharmaceutical companies - which are well established in Switzerland, but for which the Swiss domestic market is…
